FMO5 and Alzheimer disease: Future work will determine whether the in vitro findings we report here can be extended to the in vivo situation, but if so, they suggest that the use of Fpr2/3 agonists capable of reversing NADPH oxidase activation may be of therapeutic potential for AD.